PE22-28
Status
No approved product. No FDA-approved labeling exists. Not an approved medicine and never tested in a published human trial.
What it is
A spadin-derived peptide studied in mice for mood-related signaling.
What published research measured
A synthetic peptide derived from spadin, itself a fragment of the sortilin propeptide, investigated as a blocker of the TREK-1 potassium channel. That channel is a target of interest in depression research because TREK-1 knockout mice show a depression-resistant phenotype, and rodent studies of this peptide report antidepressant-like effects with a faster onset than conventional agents. The entire evidence base is preclinical. No published human trial, human pharmacokinetic data or human safety data was identified, and the peptide's stability and central nervous system penetration in people have not been established in published work.
Source
Not tied to a single designated source; see the published research on this molecule
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.